2017, Number S1
<< Back Next >>
Rev Mex Anest 2017; 40 (S1)
Updates on the management of preeclampsia
Rodríguez-Valenzuela C
Language: Spanish
References: 8
Page: 14-15
PDF size: 128.14 Kb.
Text Extraction
No abstract.
REFERENCES
Ghulmiyyah L, Sibai B. Maternal mortality from preeclampsia-eclampsia. Semin Perinatol. 2012;36:56-59.
Mortalidad Materna en México 2014. Disponible en: http://www.omm.org.mx
American College of Obstetricians and Gynecologists. ACOG Guidelines: Hypertension in pregnancy. American College of Obstetricians and Gynecologists. 2013.
Staff AC, Benton SJ, von Dadelszen P, Roberts JM, Taylor RN, Powers RW, et al. Redefining preeclampsia using placenta-derived biomarkers. Hypertension. 2013;61:932-942.
Thadhani R, Hagmann H, Schaarschmidt W, Roth B, Cingoez T, Karumanchi SA, et al. Removal of soluble fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J Am Soc Nephrol. 2015;27:903-913.
Easterling TR. Apheresis to treat preeclampsia: insights, opportunities and challenges. Am Soc Nephrol. 2016;27:663-665.
Craici IM, Wagner SJ, Weissgerber TL, Grande JP, Garovic VD. Advances in the pathophysiology of pre-eclampsia and related podocyte injury. Kidney Int. 2014;86:275-285.
Gillis EE, Mooney JN, Garrett MR, Granger JP, Sasser JM. Sildenafil treatment ameliorates the maternal syndrome of preeclampsia and rescues fetal growth in the dahl salt-sensitive rat. Hypertension. 2016;67:647-653. Available in: http://hyper.ahajournals.org/content/hypertensionaha/67/3/647.full.pdf
Full text